Sumitomo Pharma Co., Ltd. (DNPUF)
OTCMKTS
· Delayed Price · Currency is USD
4.000
0.00 (0.00%)
At close: Jan 21, 2025
Sumitomo Pharma Revenue
Sumitomo Pharma had revenue of 90.07B JPY in the quarter ending September 30, 2024, with 17.05% growth. This brings the company's revenue in the last twelve months to 342.67B, down -11.89% year-over-year. In the fiscal year ending March 31, 2024, Sumitomo Pharma had annual revenue of 314.56B, down -43.38%.
Revenue (ttm)
342.67B JPY
Revenue Growth
-11.89%
P/S Ratio
n/a
Revenue / Employee
68.81M JPY
Employees
4,980
Market Cap
1.43B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 314.56B | -240.99B | -43.38% |
Mar 31, 2023 | 555.54B | -4.49B | -0.80% |
Mar 31, 2022 | 560.04B | 44.08B | 8.54% |
Mar 31, 2021 | 515.95B | 33.22B | 6.88% |
Mar 31, 2020 | 482.73B | 23.47B | 5.11% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |